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ABSTRACT
The aims of the study were to examine the prevalence of positive mucinous ovarian carcinoma
(MOC) at different stages as well as to investigate the age at diagnosis and histological type, and to
assess the correlation between the carcinoembryonic antigen/ cancer antigen 125 (CEA/CA 125)
tests and the diagnosis of ovarian cancers retrospectively, to promote the prognosis and patient’s
health outcome. Descriptive a cross-sectional correlational design was used to examine the prevalence of positive ovarian cancer over a period of seven years of follow-up between 2010 and 2016.
All study analysis was performed using SPSS version 22. P<0.05 was taken to indicate a statistically significant value. We found that about 70% of cases showed elevation of CEA marker and about
95% of them showed elevation of Ca125. The age-specific incidence rate increased greatly in
women aged 50 years or older. The majority of the patients had stage III or IV disease. Our study
results can be used as a detection method of possible new ovarian cancer cases in an early stage and
would provide a quick non-invasive screening method for women with strong risk factors such as
old age, smoking, family history, history of other tumors and obesity.
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INTRODUCTION
Ovarian cancer has a high mortality rate
among gynecological malignancies of the
female reproductive system and is the 5th
cause of cancer death in women [1]. In Jordan, ovarian cancer is one of the top ten tumors among Jordanian females and accounts
about 2.8%[2]. The annual mortality rate per
100,000 Jordanian people from ovarian cancer has increased by 20.7% since 1990, an
average of 0.9% a year, as described by the
cancer registry of Jordanian ministry of
health in 2013.
The ovarian neoplasms which comprise
several histologic types and grades are classified into surface epithelial-stromal tumors,
sex cord-stromal tumors, and germ cell tumors. The epithelial neoplasms which are the
most common types of ovarian cancer are
classified into serous, endometrioid, mucinous, clear cell and undifferentiated subtypes.
Mucinous carcinoma of the ovary is a rare
ovarian cancer that is distinct from other epithelial subtypes based on specific clinical,
histologic, and molecular features accounting

about 7% to 14% of all primary epithelial
ovarian cancer [3].
Mucinous tumors of the ovary include a
spectrum of neoplastic disorders, including
mucinous cystadenoma, mucinous tumor of
low malignant potential (borderline) and invasive mucinous ovarian carcinoma (MOC).
The diagnosis and classification of mucinous
tumors has been problematic and controversial. The pathologic diagnosis of MOC to
differentiating benign, borderline (low malignant potential), and metastatic tumors from
primary invasive MOC is very difficult to
determine and challenging, so the true incidence is not clear yet [4]. However; the benign mucinous tumors account for 10–15 %
of all benign ovarian neoplasms tumors, borderline (low malignant potential) tumors account for 67 % of tumors not considered
strictly benign either potentially malignant
and thus are more common than invasive
MOC [5].
In a previous study in Jordan for assessment of the knowledge and awareness of Jordanian women about ovarian cancer showing
that patients came with most symptoms as the
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following: extreme fatigue (43.2%), back
pain (42.4%) and persistent pain in pelvic
area (40.7%) and the most commonly known
risk factor was smoking (68.4%) [8]. Definite
diagnosis is essential for appropriate treatment, failure to diagnose benign or borderline
histology results in inaccurate treatment, and
failure to identify other ovarian disease as
metastatic leads to a missed diagnosis of a
gastrointestinal primary and incorrect therapy
[6]. The early detection of ovarian neoplasms
is hampered by the lacking of appropriate
tumor markers and of clinically significant
symptoms until the disease reaches an advanced stage. For the same reasons, ovarian
cancer has the highest fatality-to-case ratio of
all gynecological malignancies and the worst
prognosis [7].
The aims of the study were to examine
the prevalence of positive MOC at different
stages as well as to investigate the age at diagnosis and histological type, and to assess
the correlation between the carcinoembryonic
antigen/ cancer antigen 125 (CEA/CA 125)
tests and the diagnosis of ovarian cancers
retrospectively, to promote the prognosis and
patient’s health outcome, because early diagnosis carries a high survival rate reaching
93%.
Materials and Methods
A Descriptive cross-sectional correlation
design was used. Data were collected from
women diagnosed of ovarian cancer over a
period of seven years of follow-up (between
2010 and 2016) with convenience obtained
list of women’s hospital admission number
(ID) from the admission office. Inpatients
and outpatients were recruited if they had a
diagnosis of current or had a recurrent mutinous cancer. Both malignant and borderline
diagnoses were recruited. Only the principal
investigator and the associated research team
had access to the de-identified data set.
Power analysis estimated a sample of 150
participants to achieve the power of 0.95
which represent the chance of finding an association between study variables, and effect
size of 0.3 to represent the likelihood of detecting an association between the pathology
testing and other predictors at alpha level of
0.05 to incorrectly rejecting the null hypothesis [8].

The participants’ pathology profile, laboratory testing and diagnosis report were
collected retrospectively. Each subject was
assigned an identification number to collect
the needed data retrospectively. Participants’
information was kept confidential in a secure
encrypted Excel and SPSS computer file. The
principal investigator and the associated research team only had access to the deidentified data file.
Data was coded and handled by the principal investigator and kept in a password protected computer file for data entry and analysis. Permission to access data file was given
to certified research team member who participated in data entry or analysis. The principal investigator created a code book to use
during data entry and analysis. The investigator did not withdraw any additional blood or
pathology samples from the study participants. For the purposes of this study, the results of previously performed laboratory
samples were collected.
Inclusion Criteria
The pathology reports of female patients
who had been diagnosed as mucinous ovarian
tumors either benign, borderline or malignant
types were collected. The patients could be
menopausal, premenopausal or either young.
Peritoneal fluids were also sent for diagnosis
to pathology lab to determine if these are
positive or negative in ovarian cancer because they will affect the stage of the tumor
and the prognosis. Then we correlated them
with the serologic markers such as CA125
and carcinoembryonic antigen (CEA).
Exclusion Criteria
We excluded any patient who had endometriosis, fibroids, acute pelvic inflammatory
disease, menstruation, the first trimester of
pregnancy or known case of tumor such as
hepatic or pancreatic in origin because these
conditions also elevate the serologic markers
described above, that will give false positivity.
Statistical analysis
To achieve the study objectives, the researcher used descriptive statistics of percentages,
means, medians and standard deviations to
identify the prevalence of ovarian cancer at
different stages. All study analysis was performed using SPSS version 22. P<0.05 was
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taken to indicate a statistically significant
value.
Results and discussion
The results of our study revealed that 126
cases are classified as benign (85%),16 cases
as borderline (10%) and 8 cases as malignant
(5%) (Table 1). The rate at which women are
diagnosed with ovarian cancer has been
slowly falling over the past 20 years. These
tumors occur most commonly in premenopausal women, as well as postmenopausal
patients. The age at diagnosis of MOC which
seems to be younger than the other epithelial
ovarian cancer, is usually described between
ages 20–50 years [9], However; the mean age
provided by our study was 50 (standard deviation, ±16 years). Table 1 shows the distribution of ovarian cancers based on classification and patient characteristics.
Table (1): Distribution of ovarian cancers
based on classification and patient characteristics
Variable
Frequency (%)
150 (100)
Classification total
Benign
126 ( 85%)
Borderline
16 (10%)
Malignant
8 (5%)
150 (100)
Age total
<15
1 (0.6)
15-25
7 (4.7)
25-40
10 (6.7)
40-54
90 (60)
55-64
35 (23.4)
65+
7 (4.6)
13(100)
Stage total*
0
0
I
1(7.7)
II
3 (23)
III
5 (38.5)
IV
4 (30.8)
150 (100)
Cyst side total
Right
53 (35.4)
Left
97 (64.6)
*Only the malignant subtype is included
About 70% (9 out of 13 cases) of the invasive MOC were diagnosed in advanced
stages (stage III or VI), because of lacking of
an early screening method for ovarian cancer.
However; in another study, 17 % of patients
with MOC were stage II or higher at the time

of diagnosis, the remainder were diagnosed at
stage1 [10]. Most of the mucinous tumors are
unilateral, as showed by our results in which
83% of our patients had unilateral tumor.
This result is also seen in a large retrospective series and a SEER database analysis
have both shown that 79 % of mucinous tumors are unilateral and borderline mucinous
ovarian tumors were less likely bilateral (7
%) [11]. Most of the cases showed left sided
predominate (64.6%). Positive result of cytological peritoneal fluid was 95% in the malignant subtype, however: the benign and
borderline cases exhibited negative results
100% ( p= 0.04).
Mucinous cystadenomas usually occur as
a large, multiloculated cystic mass filed with
mucus-containing fluid. The mean size at
presentation was 8 cm as showing by our
study, but the invasive one was extremely
larger. The large size can itself sometimes
suggest a mucinous histology. Specimen integrity was divided into capsule intact (60%),
capsule ruptured (35%) and fragmented
(5%). The diagnosis of ovarian cancer depends on clinical features, ultrasound imaging and serum biomarker cancer antigen 125
(CA125) [12]. CA-125 is tumor marker or
biomarker that may be elevated in the blood
of some patients with specific types of cancers, or other conditions that are benign including endometriosis, fibroids, hemorrhagic
ovarian cysts, acute pelvic inflammatory disease, menstruation and first trimester pregnancy. Carcinoembryonic antigen (CEA) is
the most useful serum tumor marker to identify MOC preoperatively and to follow the
progress of a patient with MOC postoperatively [13]. We found that about 70% of
cases showed elevation of CEA marker and
about 95% of them showing elevation of
Ca125 (p=0.045). Although these markers
are not specific but may be used in women
with risk factor as screening method to detect
mucinous ovarian tumor in early stage. In
this study, the management and the survival
rate of all patients were not recorded so can’t
be mentioned in our study.
CONCLUSIONS
Our study results can be used as detection method of possible new ovarian cancer
cases in an early stage and would provide a
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quick non-invasive screening method for
women with strong risk factors such as old
age, smoking, family history, history of other
tumors and obesity. In our country, the lack
of reliable screening modalities has restricted
the opportunities for early diagnosis and cancer detection, leading to a significant proportion of women worldwide presenting at an
advanced stage of the disease. Due to this late
presentation, available treatments are ineffective, and the majority of patients relapse following treatment-induced regression. Until
recently, all epithelial ovarian cancers have
been eligible for the same clinical trials, and
treatment recommendations have been generalized to specific subtypes. Although the
clinical decision making and prognostic information have been applied in a similar fashion to all subtypes, there is a difference in
clinical behavior, outcomes and survival rate
between MOC and other more common histologic subtypes. Patients with advanced mucinous ovarian cancer have a worse response
to chemotherapy compared with patient with
other histologic subtypes of epithelial ovarian
cancer which their survival rate is also better
than MOC [3].
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